CONDITION

Lymphoplasmacytic Enteritis

Lymphoplasmacytic enteritis describes a pattern of persistent inflammation in the small intestine, where particular types of immune cells—lymphocytes and plasma cells—gather in numbers higher than usually seen in healthy tissue. This inflammation can interfere with how the gut absorbs nutrients and how comfortably it moves food through. It sits within a broader group of conditions sometimes called inflammatory bowel disease, though that term is used differently across contexts. Owners often arrive at this page because their dog or cat has been experiencing ongoing digestive signs—loose stools, weight loss despite eating, occasional vomiting, or a coat that has lost condition. These signs tend to build gradually rather than appearing suddenly, and they may come and go over weeks or months. The condition is confirmed through biopsy, not through symptoms alone, so many owners are seeking to understand what the diagnosis means and what has been found in their pet's tissue. This page explores the signals that can appear in affected animals, the mechanisms that may drive the inflammation, the investigations used to reach and refine the diagnosis, and the range of approaches—dietary, medical, and supportive—that may be considered in managing the condition over time.

Why this matters now

Lymphoplasmacytic enteritis can appear at any age, though it tends to be recognised more often in middle-aged to older dogs and cats. Certain breeds, including German Shepherds, Soft-Coated Wheaten Terriers, and Basenjis among dogs, and domestic shorthair cats, may be seen more frequently in clinical case series, though the condition is not exclusive to these groups. In some animals, the onset appears to follow a period of dietary change, stress, or gastrointestinal infection, though in many cases no clear precipitating event can be identified.

The condition typically builds over weeks to months rather than appearing suddenly, with signs often fluctuating in intensity. Some animals experience long stretches of relative calm punctuated by flare-ups, whilst others show a more steady, persistent pattern. The course can vary considerably between individuals, and the degree of inflammation seen on biopsy does not always map neatly onto the severity of signs an owner observes at home.

Signals & patterns

Early signals

Softening or loosening of stools

Faeces may become less formed, sometimes appearing greasy or poorly shaped, though not necessarily watery at first. The change can be subtle and may be noticed over several days or weeks rather than overnight.

Gradual weight loss despite eating

An animal may maintain or even increase appetite yet lose body condition steadily. This reflects poor absorption of nutrients in the inflamed small intestine, even when food intake appears normal.

Occasional vomiting

Vomiting may occur sporadically, often with no clear pattern or trigger. It tends to be intermittent rather than daily, and the vomited material may contain food, bile, or frothy liquid.

Coat quality declining

The fur may lose shine, become drier, or feel coarser to the touch. This change often accompanies poor nutrient absorption and can be noticed before weight loss becomes obvious.

Increased gut sounds or discomfort

Some animals develop audible borborygmi—rumbling or gurgling from the abdomen—or show signs of mild discomfort such as shifting position frequently or a tense posture after eating.

Later signals

Persistent or watery diarrhoea

As inflammation progresses, stools may become more consistently loose or liquid, sometimes with a greasy appearance. Frequency may increase, and accidents in the house can occur in animals previously reliable.

Marked muscle loss and weakness

Muscle wasting, particularly visible along the spine and over the hindquarters, can become pronounced. Some animals tire more easily on walks or show less interest in activities they previously enjoyed.

Reduced appetite or selective eating

In some cases, appetite begins to wane or the animal becomes choosier about food, possibly reflecting nausea or learned associations between eating and discomfort.

Click to read about the biological mechanisms

How this is usually investigated

Investigation typically begins with a detailed history and physical examination, building a picture of the pattern and duration of signs, dietary history, and any previous treatments. Blood tests and imaging help rule out other causes of chronic digestive signs, such as organ disease, parasites, or structural abnormalities. Definitive diagnosis rests on biopsy of the intestinal lining, which reveals the density and type of immune cells present and the degree of architectural change in the tissue.

Blood biochemistry and haematology

Purpose: These tests assess protein levels, liver and kidney function, electrolyte balance, and red and white blood cell counts. Low albumin or total protein can suggest protein loss through the gut, whilst other changes may point to concurrent organ involvement or secondary effects of malabsorption.
Considerations: Results can be normal even when intestinal inflammation is present, particularly in milder cases. The tests help exclude other conditions but do not confirm lymphoplasmacytic enteritis on their own.

Faecal examination and testing

Purpose: Microscopy and specific tests for parasites, bacterial pathogens, and protozoal organisms help exclude infectious causes of chronic diarrhoea. Some tests also measure faecal markers of inflammation or protein loss.
Considerations: A negative result does not rule out all infectious contributors, and some animals may have both infection and inflammation present. Interpretation depends on the clinical picture and may require repeat sampling.

Diagnostic imaging

Purpose: Abdominal ultrasound or radiography can reveal thickening of the intestinal wall, changes in the layering of gut tissue, enlarged lymph nodes, or masses that might suggest lymphoma or other structural disease. Ultrasound can also guide fine-needle aspiration of abnormal nodes.
Considerations: Imaging findings in lymphoplasmacytic enteritis can be subtle or absent, and wall thickening alone does not distinguish between different types of inflammation or neoplasia. Biopsy remains necessary for definitive characterisation.

Intestinal biopsy

Purpose: Tissue samples taken via endoscopy or surgical biopsy allow a pathologist to examine the density and distribution of lymphocytes and plasma cells, assess the integrity of the villi, and distinguish lymphoplasmacytic enteritis from other inflammatory patterns or lymphoma. The biopsy also provides information on the degree of architectural disruption.
Considerations: Endoscopic biopsy samples the superficial layers and may miss deeper changes; full-thickness surgical biopsy captures more tissue but involves greater anaesthetic and recovery considerations. Sampling error can occur if inflammation is patchy, and interpretation depends on the experience of the pathologist.

Dietary trial

Purpose: Feeding a novel protein or hydrolysed diet for several weeks can help determine whether signs improve with dietary change alone, which may suggest a food-responsive component to the inflammation. Response to diet can inform both diagnosis and management.
Considerations: A dietary trial requires strict adherence, with no treats or table food, which can be challenging in multi-pet households or for cats with strong food preferences. Lack of response does not rule out dietary involvement, as some animals may require both dietary and medical management.

Options & trade-offs

Management is usually built from a combination of dietary adjustment, immune-modulating medication, and supportive care, tailored to the individual animal's response and the owner's capacity to implement different strategies. Some animals stabilise with diet alone, whilst others require ongoing medication to maintain comfort and bodyweight. The aim is to reduce inflammation, support nutrient absorption, and minimise flare-ups, recognising that the condition may fluctuate over time and that what works well in one phase may need adjustment later.

Dietary modification

This often involves switching to a diet with a novel protein source the animal has not previously eaten, or a hydrolysed diet in which proteins are broken into fragments too small to trigger immune recognition. The diet is fed exclusively for several weeks to assess response. Some animals show improvement in stool quality, weight, and coat condition with dietary change alone, suggesting that components of the previous diet were contributing to the inflammation.

Trade-offs: Success depends on strict adherence, which can be difficult if the animal is a reluctant eater or lives in a household with other pets. Some animals do not respond to diet alone and require additional medical management. Hydrolysed diets can be costly, and palatability varies between brands and individual animals.

Immunosuppressive medication

Corticosteroids such as prednisolone are often used to dampen the immune response driving the inflammation, reducing the density of lymphocytes and plasma cells in the intestinal wall. The dose is typically started at a higher level and then tapered over weeks to months, aiming for the lowest effective dose. In some cases, other immunosuppressive agents may be considered—azathioprine in dogs, which is not recommended in cats owing to their heightened sensitivity to its myelosuppressive and hepatotoxic effects, or chlorambucil, which is used in both species and is the preferred second-line agent in cats—particularly if corticosteroids alone are insufficient or poorly tolerated.

Trade-offs: Corticosteroids can increase thirst, appetite, and urination, and long-term use carries risks including weight gain, muscle loss, and increased susceptibility to infection. Tapering too quickly may lead to relapse, whilst prolonged high doses increase the likelihood of side effects. Monitoring through follow-up examinations and bloodwork is usually necessary.

Antimicrobial therapy

Antibiotics such as metronidazole or tylosin are sometimes used for their anti-inflammatory and immune-modulating effects in the gut, rather than to target a specific pathogen. These medications may alter the balance of intestinal bacteria in ways that reduce inflammation. They are often used in combination with dietary change or immunosuppressive medication.

Trade-offs: The benefit of antibiotics in lymphoplasmacytic enteritis is variable, and prolonged use raises concerns about disrupting the normal gut microbiome and contributing to antimicrobial resistance. Response can be difficult to predict, and some animals show little improvement with antimicrobials alone.

Cobalamin and other vitamin supplementation

Many animals with chronic small intestinal inflammation have low blood levels of cobalamin (vitamin B12), either because of malabsorption or depletion of the bacteria that synthesise it in the gut. Parenteral cobalamin injections can restore levels and may improve appetite, energy, and gastrointestinal function. Other vitamins, such as folate, may also be supplemented if deficiency is detected.

Trade-offs: Supplementation addresses a consequence of the inflammation rather than the inflammation itself, so it is usually part of a broader management plan rather than a sole intervention. Injections require handling and repeat visits, though many owners become comfortable administering them at home over time.

Probiotic and prebiotic use

Some owners and veterinary professionals consider probiotics or prebiotics as part of a strategy to support a healthier balance of gut bacteria, on the premise that shifts in the microbiome may contribute to or result from the inflammation. Evidence for benefit in lymphoplasmacytic enteritis specifically is limited, and products vary widely in strain, dose, and quality.

Trade-offs: Probiotics are generally well tolerated, but response is inconsistent and difficult to measure. They are unlikely to replace dietary or medical management in animals with significant inflammation, though some owners find them a useful adjunct. Cost and the need for ongoing administration are practical considerations.

Common misconceptions

Misconception:

"If my pet's stools look normal again, the inflammation has resolved and treatment can stop."

Reality:

Improvement in stool quality often reflects better control of inflammation rather than complete resolution of the underlying immune cell infiltration. Stopping treatment abruptly can lead to relapse, as the inflammatory process may still be active at a tissue level even when outward signs have settled. Changes to medication or diet are usually made gradually, with monitoring for recurrence of signs.

Misconception:

"Lymphoplasmacytic enteritis will turn into cancer if not treated aggressively."

Reality:

Lymphoplasmacytic enteritis and intestinal lymphoma are distinct conditions, though they can sometimes be difficult to distinguish on biopsy, particularly if sampling is limited. There is ongoing discussion in the veterinary literature about whether chronic inflammation can, in some cases, progress to lymphoma, but this is not a predictable or inevitable trajectory. The aim of management is to control inflammation and maintain quality of life, not to prevent a transformation that may not occur.

Misconception:

"A hypoallergenic diet will cure the condition, so medication is unnecessary."

Reality:

Dietary change can be highly effective in some animals, leading to substantial improvement or even resolution of signs, but others require medical management in addition to diet to control inflammation adequately. The response to diet alone varies widely, and whether an animal will be diet-responsive cannot be reliably predicted in advance. A trial period is usually needed to assess the degree of benefit.

Related conditions

Eosinophilic Enteritis

Eosinophilic enteritis shares the pattern of chronic immune-cell infiltration in the small intestine, differing chiefly in the predominant cell type found on biopsy. Both conditions sit within the broader category sometimes termed inflammatory bowel disease, and they can present with overlapping signs such as weight loss, diarrhoea, and vomiting.

Intestinal Lymphangiectasia

Intestinal lymphangiectasia can occur alongside lymphoplasmacytic enteritis or may develop as a consequence when chronic inflammation damages the lymphatic vessels in the intestinal wall. Both conditions can lead to protein loss through the gut, and distinguishing or identifying them together often requires biopsy and careful interpretation of tissue changes.

Protein-Losing Enteropathy

Protein-losing enteropathy describes the functional consequence—loss of protein into the intestines—that can arise from lymphoplasmacytic enteritis when inflammation disrupts the gut lining sufficiently. An animal with lymphoplasmacytic enteritis may develop this pattern, particularly if the inflammation is severe or widespread.

Alimentary Lymphoma in Cats

Alimentary lymphoma in cats can present with signs that overlap substantially with those of lymphoplasmacytic enteritis, including chronic vomiting, weight loss, and intestinal thickening. Biopsy is needed to distinguish the two, as both involve lymphocyte accumulation in the gut, though lymphoma represents uncontrolled proliferation rather than inflammatory infiltration.

Food Allergy in Dogs

Food allergy in dogs can trigger or contribute to intestinal inflammation that may appear similar to lymphoplasmacytic enteritis, and dietary trial is often part of the diagnostic and therapeutic approach for both. In some cases, the immune response to dietary protein may underlie or perpetuate the pattern of lymphocyte and plasma cell infiltration seen on biopsy.

Lymphoplasmacytic enteritis sits within a broader landscape of conditions affecting nutrient absorption, immune regulation, and gut health, many of which share overlapping signs and may benefit from similar investigative and management approaches. Exploring related conditions within the metabolic health pillar, or conditions involving chronic inflammation in other systems, can provide context for patterns observed over time. Conversations about monitoring for relapse, adjusting treatment as the animal ages, or managing concurrent conditions may become relevant as the picture develops.